Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemiaRiccardo Moia, Gianluca Gaïdano, Riccardo Dondolin et al.|Hematological Oncology|2022Cited by 4
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia studyFrancesco Autore, Luca Laurenti, Idanna Innocenti et al.|Hematological Oncology|2023Cited by 2
Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic LeukemiaValentina Griggio, Marta Coscia, Candida Vitale et al.|Blood|2024Cited by 1
Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?Francesco Autore, Luca Laurenti, Alessandra Tedeschi et al.|Blood|2023Cited by 0
Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre StudyFrancesco Autore, Luca Laurenti, Ilaria Del Giudice et al.|Blood|2024Cited by 0